Epocrates
For u.S.-based healthcare professionals including physicians, nurse practitioners, and pharmacists requiring rapid drug information at the point of care.
Known forepocrates: Drug Info & Pill ID
epocrates: Drug Info & Pill IDFor u.S.-based healthcare professionals including physicians, nurse practitioners, and pharmacists requiring rapid drug information at the point of care.
epocrates: Drug Info & Pill IDProviding U.S. healthcare professionals with point-of-care clinical decision support tools to improve prescribing safety and efficiency.
Target audience
Portfolio
Free 1Last updated
epocrates: Drug Info & Pill ID
v26.4.0
3mo ago
Primary focus
Clinical decision support and medical reference tools
Scale
indie
Target audience
U.S.-based healthcare professionals including physicians, nurse practitioners, and pharmacists requiring rapid drug information at the point of care.
Maintains an intense development cadence with 11 updates in the last 6 months for its single flagship medical reference title.
1 app analysed
Unique 30-drug interaction checker and visual Pill ID
0
Positive apps
0
Neutral / mixed
1
Negative apps
24/100
Avg sentiment score
MDCalc matches the target's scale (51k vs 33k ratings) and high-frequency utility, serving as the primary alternative for clinical decision-making tools.
Strategic outlook coming soon.
What fed this analysis
Strong clinical decision support alternative with a high rating (4.87) and active maintenance.
A high-authority clinical reference with 11k+ ratings and a consistent release cadence (6 in 6 months).
A direct utility rival with 13k+ ratings, backed by the WebMD ecosystem.
While a social network, its massive scale (191k ratings) and 24 releases in 6 months make it a dominant presence on clinician home screens.
A legacy reference standard that remains highly rated and recently updated.
Acts as an aggregator for multiple medical resources, including drug guides.
Directly targets the 'busy clinician' persona with a similar 'quick-glance' value proposition.
An emerging threat focusing on visual/case-based learning with a very recent update (April 2026).
